| Literature DB >> 27222657 |
Behdad Navabi1, Julia Elizabeth Mainwaring Upton2.
Abstract
BACKGROUND: Eosinophilia is not an uncommon clinical finding. However, diagnosis of its cause can be a dilemma once common culprits, namely infection, allergy and reactive causes are excluded. Primary immunodeficiency disorders (PID) are among known differentials of eosinophilia. However, the list of PIDs typically reported with eosinophilia is small and the literature lacks an inclusive list of PIDs which have been reported with eosinophilia. This motivated us to review the literature for all PIDs which have been described to have elevated eosinophils as this may contribute to an earlier diagnosis of PID and further the understanding of eosinophilia.Entities:
Keywords: Eosinophilia; Eosinophilia differentials; Primary immunodeficiency disorders; Severe eosinophilia
Year: 2016 PMID: 27222657 PMCID: PMC4878059 DOI: 10.1186/s13223-016-0130-4
Source DB: PubMed Journal: Allergy Asthma Clin Immunol ISSN: 1710-1484 Impact factor: 3.406
Primary immunodeficiency disorders associated with eosinophilia
| PID | Genetic defect/subtype (s) | Functional defect | Inheritance | AEC range (× 109/L)b |
|---|---|---|---|---|
| Combined immunodeficiencies | ||||
| ADA Deficiency | Late onset ADA | Elevated lymphotoxic metabolites | AR | 0.8–4.7 |
| ZAP70 deficiencya | ZAP70 | Intracellular signaling abnormality | AR | 9.5 |
| CD3γ deficiencya |
| T-cell receptor expression defect | AR | 0.2–0.7 |
| MHC II deficiencya |
| Impaired antigen presentation by APCs | AR | 3–10 |
| TCR α deficiency |
| T-cell receptor generation | AR | 0.08–2.5 |
| MALT1 deficiency |
| NF-kB activation failure | AR | Not specified |
| OSa |
| T-cell receptor generation abnormality | AR | 0.1–21.8 |
|
| Defect in IL-7 receptor α chain | AR | 6.49 | |
|
| Cytokine receptor signaling abnormality | AR | 15.56 | |
| 22q11.2 | DiGeorge syndrome | AD | 1.36– >15 | |
|
| Chromatin organization defects | AR | 1.3–4.1 | |
|
| DNA DSB repair defect | AR | 2.12 | |
|
| Elevated lymphotoxic metabolites | AR | 0.85–1.73 | |
|
| Mitochondrial RNA processing defects | AR | Not specified | |
|
| TCR/BCR induced NF-kB activation failure | AR | Not specified | |
|
| DNA repair defect | AR | Not specified | |
| Combined immunodeficiencies with associated or syndromic features | ||||
| Ataxia-Telangiectasia |
| DNA break repair defect | AR | Not specified |
| WASa |
| Actin cytoskeleton abnormality | AR | 0–8.32 |
| NS |
| Pro-Th2 and stratum corneum detachment | AR | Not specified |
| HIES |
| Intracellular signaling abnormality | AD | 0.029–54.81 |
|
| Cytokine signaling abnormality | AR | 0.29–0.8 | |
|
| Cytoskeletal organization defects | AR | 0.245–37.88 | |
| Predominantly antibody deficiencies | ||||
| CVID | Unknown | Unknown | Variable | 0.385–1.562 |
| CD40L deficiency |
| Defects in Ig isotype switching | XL | 0.5–1.5 |
| CD40 deficiencya |
| Defects in Ig isotype switching | AR | 0.8–13.5 |
| Selective IgA deficiency | Unknown | 0.672 | ||
| Diseases of immune dysregulation | ||||
| IPEXa |
| Dysfunction of regulatory Tcells | XL | 0.236–8.423 |
| ALPSa |
| Failure of apoptosis | AD | 1.33–35.46 |
| Otherc | Failure of apoptosis | Not specified | ||
| Congenital defects of phagocyte number or function or both | ||||
| Kostmann disease |
| Control of apoptosis | AR | 0.09–1.30 |
| Cyclic neutropenia |
| “Gain-of-function” in the neutrophil granule | AD | Not specified |
| STAT1 deficiencya |
| IFN-γ signalling defect | AD | 11.1 |
| PLS |
| Defective chemotaxis of PMNs | AR | 0.96–2.156 |
| CGD |
| Neutrophil oxidative burst deficiency | XL | 0.786 |
| Defects of innate immunity | ||||
| EDA-ID |
| Failure of NEMO-induced NF-κB activation | XL | 1.45 |
| CARD9 deficiency |
| Selective defect in defense against fungal infection | AR | Not specified |
| Autoinflammatory disorders | ||||
| NOMID/CINCA |
| Defect in regulation of inflammation and apoptosis | AD | 0.728–3.441 |
| Blau syndrome |
| NF-κB activation causing excess inflammatory cytokine | AD | Not specified |
| Not classified by IUIS | ||||
| PGM3 deficiency |
| Possibly signalling defects | AR | 0–3.6 |
| Roifman syndrome |
| Disrupted minor intron splicing | AR | Not specified |
aConditions with severe eosinophilia
bThe absolute eosinophil count(s) with further details and source references in Additional file 1: Table S1
c TNFSF6 or CASP8 or CAS10
Fig. 1A Severity-Based Approach to Assessing for PIDs which have been reported with Eosinophilia. The initial approach presented here is based on the history and physical exam and simple laboratory tests. This assessment may reveal independent indications for PID evaluation independent of eosinophilia. In an infant we suggest a low threshold to consider SCID and Omenn syndrome. A consideration of transplantable/severe PIDs is presented next with some phenotypic clues. Then HIES and similarly presenting conditions may be considered in patients with eczematous dermatitis ± high IgE including performing the NIH score for STAT3 deficiency. Finally, phenotypic clues for other PIDs which have been reported with eosinophilia are listed. This approach does not suggest to evaluate all patients for all disorders but to begin with considering severe causes and then let the phenotype guide investigations for particular conditions. A few conditions, such as WAS and STAT3, appear in multiple locations due to variable presentations